Kaposi's Sarcoma
Karen Hamm Antman, Yuan Chang · New England Journal of Medicine · 2000
In 1872, Moritz Kaposi, a Hungarian dermatologist, described five men with aggressive “idiopathic multiple pigmented sarcomas of the skin.”1 One patient died of gastrointestinal bleeding 15 months after the initial appearance of the skin lesions, and an autopsy showed visceral lesions in the lungs and the gastrointestinal tract. Subsequently, other investigators described four clinical variants of Kaposi's sarcoma that had identical histologic features but developed in specific populations and had different sites of involvement and rates of progression (Table 1). In the light of recent discoveries regarding the viral pathogenesis of Kaposi's sarcoma, these variants most likely represent different manifestations . . .
Cited by 1,023 works. doi:10.1056/nejm200004063421407
Authors
References
- Identification of Herpesvirus-Like DNA Sequences in AIDS-Sssociated Kaposi's Sarcoma
- Kaposi's sarcoma among persons with AIDS: a sexually transmitted infection?
- Viral FLICE-inhibitory proteins (FLIPs) prevent apoptosis induced by death receptors
- Nucleotide sequence of the Kaposi sarcoma-associated herpesvirus (HHV8)
- Detection of Kaposi sarcoma associated herpesvirus in peripheral blood of HIV-infected individuals and progression to Kaposi's sarcoma
- Kaposi's sarcoma in Uganda: A clinico‐pathological study
- KSHV antibodies among Americans, Italians and Ugandans with and without Kaposi's sarcoma
- The seroepidemiology of human herpesvirus 8 (Kaposi's sarcoma–associated herpesvirus): Distribution of infection in KS risk groups and evidence for sexual transmission
- The microtubule-affecting drug paclitaxel has antiangiogenic activity.
- Primary characterization of a herpesvirus agent associated with Kaposi's sarcomae